Unknown

Dataset Information

0

Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer.

ABSTRACT:

SUBMITTER: Song A 

PROVIDER: S-EPMC5864629 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease.
| S-EPMC6351406 | biostudies-literature
Unknown Role of consolidative stereotactic ablative radiotherapy in patients with oligometastatic non-small cell lung cancer.
| S-EPMC5594180 | biostudies-literature
Unknown Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer.
| S-EPMC6863405 | biostudies-literature
Unknown Stereotactic ablative radiotherapy for oligometastatic disease in liver.
| S-EPMC4020541 | biostudies-literature
Unknown Local ablative radiotherapy for oligometastatic non-small cell lung cancer.
| S-EPMC6790793 | biostudies-literature
Unknown Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial.
| S-EPMC7375645 | biostudies-literature
Unknown Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer.
| S-EPMC8335830 | biostudies-literature
Unknown Safety of stereotactic ablative body radiation for ultracentral stage I non-small cell lung cancer.
| S-EPMC6795582 | biostudies-literature
Unknown The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms.
| S-EPMC3138920 | biostudies-literature
Unknown Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care.
| S-EPMC8161824 | biostudies-literature